| [1] |
Harbeck N, Penault-Llorca F, Cortes J, et al. Breast cancer[J]. Nat Rev Dis Primers，2019，5(1):66.
|
| [2] |
Zaharia M, Gómez H. Cáncer de mama triple negativo: una enfermedad de difícil diagnóstico y tratamiento [Triple negative breast cancer: a difficult disease to diagnose and treat][J]. Rev Peru Med Exp Salud Publica，2013，30(4):649-656.
|
| [3] |
Schmadeka R, Harmon BE, Singh M. Triple-negative breast carcinoma: current and emerging concepts[J]. Am J Clin Pathol, 2014，141(4):462-477.
|
| [4] |
Brown M, Tsodikov A, Bauer KR, et al. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999-2004[J]. Cancer，2008，112(4):737-747.
|
| [5] |
Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res，2007，13(15 Pt 1):4429-4434.
|
| [6] |
Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest, 2011, 121(7):2750-2767.
|
| [7] |
Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes[J]. Clin Cancer Res, 2013，19(19):5533-5540.
|
| [8] |
Lehmann BD, Jovanovic′ B, Chen X, et al. Refinement of triple-negative breast cancer molecular aubtypes: implications for neoadjuvant chemotherapy selection[J]. PLoS One, 2016，11(6):e0157368.
|
| [9] |
Echavarria I, López-Tarruella S, Picornell A, et al. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification[J]. Clin Cancer Res, 2018, 24(8):1845-1852.
|
| [10] |
Prat A, Adamo B, Cheang MC, et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer[J]. Oncologist, 2013，18(2):123-133.
|
| [11] |
Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer[J]. Clin Cancer Res, 2015，21(7):1688-1698.
|
| [12] |
Reiche K, Kasack K, Schreiber S, et al. Long non-coding RNAs differentially expressed between normal versus primary breast tumor tissues disclose converse changes to breast cancer-related protein-coding genes[J]. PLoS One，2014，9(9):e106076.
|
| [13] |
Liu YR, Jiang YZ, Xu XE, et al. Comprehensive transcriptome profiling reveals multigene signatures in triple-negative breast cancer[J]. Clin Cancer Res, 2016，22(7):1653-1662.
|
| [14] |
Liu YR, Jiang YZ, Xu XE, et al. Comprehensive transcriptome analysis identifies novel molecular subtypes and subtype-specific RNAs of triple-negative breast cancer[J]. Breast Cancer Res, 2016，18(1):33.
|
| [15] |
Jiang YZ, Ma D, Suo C, et al. Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies[J]. Cancer Cell, 2019，35(3):428-440.
|
| [16] |
Zhao S, Ma D, Xiao Y, et al. Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance[J]. Oncologist, 2020，25(10):e1481-e1491.
|
| [17] |
Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer[J]. Clin Cancer Res, 2013，19(19):5505-5512.
|
| [18] |
Caiazza F, Murray A, Madden SF, et al. Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells[J]. Endocr Relat Cancer，2016，23(4):323-334.
|
| [19] |
Traina TA, Miller K, Yardley DA, et al. Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer[J]. J Clin Oncol, 2018，36(9):884-890.
|
| [20] |
Polivka J Jr, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway[J]. Pharmacol Ther, 2014，142(2):164-175.
|
| [21] |
André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer[J]. N Engl J Med，2019，380(20):1929-1940.
|
| [22] |
Vagia E, Mahalingam D, Cristofanilli M. The landscape of targeted therapies in TNBC[J]. Cancers (Basel), 2020，12(4):916.
|
| [23] |
Lehmann BD, Bauer JA, Schafer JM, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors[J]. Breast Cancer Res, 2014，16(4):406.
|
| [24] |
Lehmann BD, Abramson VG, Sanders ME, et al. TBCRC 032 IB/II multicenter study: molecular insights to AR antagonist and PI3K inhibitor efficacy in patients with AR+ metastatic triple-negative breast cancer[J]. Clin Cancer Res，2020，26(9):2111-2123.
|
| [25] |
Lundberg AS, Weinberg RA. Control of the cell cycle and apoptosis[J]. Eur J Cancer, 1999，35(14):1886-1894.
|
| [26] |
Fry DW, Harvey PJ, Keller PR, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts[J]. Mol Cancer Ther, 2004，3(11):1427-1438.
|
| [27] |
Asghar US, Barr AR, Cutts R, et al. Single-cell dynamics determines response to CDK4/6 inhibition in triple-negative breast cancer[J]. Clin Cancer Res, 2017，23(18):5561-5572.
|
| [28] |
Rampurwala M, Wisinski KB, O’Regan R. Role of the androgen receptor in triple-negative breast cancer[J]. Clin Adv Hematol Oncol, 2016，14(3):186-193.
|
| [29] |
Matutino A, Amaro C, Verma S. CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease[J]. Ther Adv Med Oncol, 2018, 10:1758835918818346.
|
| [30] |
Hu ZI, McArthur HL. Immunotherapy in breast cancer: the new frontier[J]．Curr Breast Cancer Rep，2018;10(2):35-40.
|
| [31] |
Sabatier R, Finetti P, Mamessier E, et al. Prognostic and predictive value of PDL1 expression in breast cancer[J]. Oncotarget, 2015，6(7):5449-5464.
|
| [32] |
Mittendorf EA, Philips AV, Meric-Bernstam F, et al. PD-L1 expression in triple-negative breast cancer[J]. Cancer Immunol Res，2014，2(4):361-370.
|
| [33] |
Adams S, Schmid P, Rugo HS, et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study[J]. Ann Oncol，2019，30(3):397-404.
|
| [34] |
Vinayak S, Tolaney SM, Schwartzberg L, et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer [J]. JAMA Oncol，2019，5(8):1132-1140.
|
| [35] |
Francica P, Rottenberg S. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response[J]. Genome Med，2018，10(1):101.
|
| [36] |
Riaz N, Blecua P, Lim RS, et al. Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes[J]. Nat Commun, 2017，8(1):857.
|
| [37] |
Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med, 2017，377(6):523-533.
|
| [38] |
Yi T, Feng Y, Sundaram R, et al. Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas[J]. Int J Cancer, 2019，145(5):1209-1220.
|
| [39] |
Fasching PA, Link T, Hauke J, et al. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)[J]. Ann Oncol，2021，32(1):49-57.
|
| [40] |
Bi Y, Verginadis II, Dey S, et al. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas[J]. Gynecol Oncol, 2018，150(3):534-544.
|
| [41] |
Lord CJ, Tutt AN, Ashworth A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors[J]. Annu Rev Med, 2015，66:455-470.
|
| [42] |
Dhillon KK, Bajrami I, Taniguchi T, et al. Synthetic lethality: the road to novel therapies for breast cancer[J]. Endocr Relat Cancer, 2016，23(10):T39-T55.
|
| [43] |
Conley SJ, Gheordunescu E, Kakarala P, et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia[J]. Proc Natl Acad Sci U S A, 2012，109(8):2784-2789.
|
| [44] |
Huang LE, Bindra RS, Glazer PM, et al. Hypoxia-induced genetic instability--a calculated mechanism underlying tumor progression[J]. J Mol Med (Berl), 2007，85(2):139-148.
|
| [45] |
Bear HD, Tang G, Rastogi P, et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer[J]. N Engl J Med, 2012，366(4):310-320.
|
| [46] |
von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer[J]. N Engl J Med, 2012，366(4):299-309.
|
| [47] |
Fasching PA, Loibl S, Hu C, et al. BRCA1/2 mutations and bevacizumab in the neoadjuvant treatment of breast cancer: response and prognosis results in patients with triple-negative breast cancer from the GeparQuinto study[J]. J Clin Oncol，2018，36(22):2281-2287.
|